Valbenazine + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obsessive-Compulsive Disorder
Conditions
Obsessive-Compulsive Disorder
Trial Timeline
Feb 1, 2026 → Dec 1, 2027
NCT ID
NCT07111988About Valbenazine + Placebo
Valbenazine + Placebo is a phase 2 stage product being developed by Neurocrine Biosciences for Obsessive-Compulsive Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07111988. Target conditions include Obsessive-Compulsive Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07111988 | Phase 2 | Recruiting |
| NCT05654870 | Phase 3 | Terminated |
| NCT04102579 | Phase 3 | Completed |
Competing Products
8 competing products in Obsessive-Compulsive Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bitopertin + Placebo + SSRI | Roche | Phase 2 | 52 |
| pregabalin + Placebo | Pfizer | Approved | 84 |
| Sertraline + Levetiracetam + Placebo | UCB | Phase 2/3 | 62 |
| Escitalopram + Placebo oral tablet | Lundbeck | Approved | 82 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 72 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 72 |
| Troriluzole + Placebo | Biohaven | Phase 2/3 | 60 |
| Nitrous Oxide + Nitrogen | Brain Biotech | Phase 2 | 44 |